Syndax Pharmaceuticals (SNDX) Change in Accured Expenses (2015 - 2026)

Syndax Pharmaceuticals' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at -$28.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 1019.19% year-over-year to -$28.3 million; the TTM figure through Mar 2026 stood at $16.4 million (down 29.87% YoY), while the FY2025 annual figure was $42.2 million, up 120.32% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$28.3 million, down from $25.7 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $25.7 million in Q4 2025, with the low at -$28.3 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $2.4 million (2023), against an average of $3.4 million.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses soared 9304.88% in 2022, then slumped 1019.19% in 2026.
• Syndax Pharmaceuticals' Change in Accured Expenses stood at $11.0 million in 2022, then tumbled by 31.58% to $7.5 million in 2023, then surged by 55.34% to $11.7 million in 2024, then surged by 120.46% to $25.7 million in 2025, then sank by 210.33% to -$28.3 million in 2026.
• Business Quant data shows SNDX's Change in Accured Expenses at -$28.3 million in Q1 2026, $25.7 million in Q4 2025, and $1.1 million in Q3 2025.